Michele Cea

List of Publications by Year
in descending order

129	4,077	147726 31	128225 60
papers	citations	h-index	g-index

130	130	130	6310
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment. Haematologica, 2022, 107, 1410-1426.	1.7	6
2	Effect of Geriatric Comanagement in Older Patients Undergoing Surgery for Gastrointestinal Cancer: A Retrospective, Before-and-After Study. Journal of the American Medical Directors Association, 2022, 23, 1868.e9-1868.e16.	1.2	7
3	Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer. European Journal of Medicinal Chemistry, 2022, 239, 114504.	2.6	5
4	Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery. Pharmaceuticals, 2022, 15, 848.	1.7	10
5	A realâ€world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. Hematological Oncology, 2021, 39, 41-50.	0.8	22
6	SIRT6 enhances oxidative phosphorylation in breast cancer and promotes mammary tumorigenesis in mice. Cancer & Metabolism, 2021, 9, 6.	2.4	25
7	Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study. Leukemia and Lymphoma, 2021, 62, 1897-1906.	0.6	1
8	Preâ€transplant minimal residual disease assessment and transplantâ€related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation. European Journal of Haematology, 2021, 107, 573-582.	1.1	7
9	Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment. Cancers, 2021, 13, 4013.	1.7	31
10	Radiomics and Artificial Intelligence for Outcome Prediction in Multiple Myeloma Patients Undergoing Autologous Transplantation: A Feasibility Study with CT Data. Diagnostics, 2021, 11, 1759.	1.3	10
11	Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden. Cancers, 2021, 13, 34.	1.7	10
12	Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells. Frontiers in Immunology, 2021, 12, 753890.	2.2	3
13	Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 1705-1720.	5.1	120
14	Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. Blood Cancer Journal, 2021, 11, 197.	2.8	5
15	Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia, 2020, 34, 234-244.	3.3	80
16	Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas. Leukemia and Lymphoma, 2020, 61, 84-90.	0.6	7
17	Fasting-mimicking diet and hormone therapy induce breast cancer regression. Nature, 2020, 583, 620-624.	13.7	198
18	Amino acid depletion triggered by ÊŸ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death. Blood Advances, 2020, 4, 4312-4326.	2.5	19

#	Article	IF	Citations
19	Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients. Leukemia and Lymphoma, 2020, 61, 1695-1701.	0.6	4
20	The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. Haematologica, 2020, 105, 2420-2431.	1.7	12
21	The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. Cancers, 2020, 12, 320.	1.7	24
22	Radiomics and artificial intelligence analysis of CT data for the identification of prognostic features in multiple myeloma. , 2020, , .		2
23	Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial. Blood, 2020, 136, 44-45.	0.6	7
24	Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation. Blood, 2020, 136, 32-33.	0.6	1
25	Abstract CT075: Fasting-mimicking diet and hormone therapy modulates metabolic factors to promote breast cancer regression and reduce side effects. , 2020, , .		0
26	Ixazomib-Based Induction Followed By Single-Agent Ixazomib Maintenance in Transplant Ineligible, Newly Diagnosed Multiple Myeloma Patients: Updated Results of the EMN10-Unito Trial. Blood, 2020, 136, 27-28.	0.6	0
27	Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRDâ€driven salvage approach. British Journal of Haematology, 2019, 186, e223-e225.	1.2	9
28	The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells. Cancers, 2019, 11, 1586.	1.7	17
29	A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia. Leukemia Research, 2019, 86, 106223.	0.4	7
30	Differentiating diffuse from focal pattern on Computed Tomography in multiple myeloma: Added value of a Radiomics approach. European Journal of Radiology, 2019, 121, 108739.	1.2	28
31	Nutrients in the Prevention of Alzheimerâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-20.	1.9	66
32	SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells. FASEB Journal, 2019, 33, 3704-3717.	0.2	48
33	Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (<scp>FLAI</scp>) provides the most useful prognostic information. British Journal of Haematology, 2019, 184, 457-460.	1.2	13
34	Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients. Blood, 2019, 134, 605-605.	0.6	3
35	Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent. Oncotarget, 2019, 10, 6723-6738.	0.8	19
36	Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study. Blood, 2019, 134, 3195-3195.	0.6	0

#	Article	IF	Citations
37	Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden. Blood, 2019, 134, 3828-3828.	0.6	0
38	Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells. European Journal of Medicinal Chemistry, 2018, 150, 457-478.	2.6	6
39	Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cellsâ€™ vulnerability to DNA-damaging agents. Haematologica, 2018, 103, 80-90.	1.7	48
40	A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML. Blood, 2018, 132, 5243-5243.	0.6	1
41	Predictive values of two frailty screening tools in older patients with solid cancer: a comparison of SAOP2 and G8. Oncotarget, 2018, 9, 35056-35068.	0.8	19
42	Abstract 793: The novel Bruton's tyrosine kinase inhibitor ARQ531 disrupts survival signaling and triggers apoptosis in AML cells. , 2018, , .		0
43	Abstract 4461: Sirt6 deletion slows mouse mammary tumorigenesis. , 2018, , .		0
44	Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against WaldenstrÃƒÂ¶m Macroglobulinemia. Blood, 2018, 132, 1585-1585.	0.6	0
45	Erwinia Chrysantemi-Derived L-Asparaginase Strongly Enhances Proteasome Inhibitors Activity By Deregulating Cell Metabolic Programs. Blood, 2018, 132, 3221-3221.	0.6	0
46	Evaluation of prognostic indices in elderly hospitalized patients. Geriatrics and Gerontology International, 2017, 17, 1015-1021.	0.7	10
47	Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood, 2017, 129, 2233-2245.	0.6	33
48	Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair. Cancer Research, 2017, 77, 3857-3869.	0.4	81
49	Validation of the photography method for nutritional intake assessment in hospitalized elderly subjects. Journal of Nutrition, Health and Aging, 2017, 21, 614-621.	1.5	13
50	Pharmacological Sirt6 inhibition improves glucose tolerance in a type 2 diabetes mouse model. FASEB Journal, 2017, 31, 3138-3149.	0.2	62
51	Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin. , 2017, 7, 603-621.		78
52	SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects. Bioorganic and Medicinal Chemistry, 2017, 25, 5849-5858.	1.4	37
53	Biological Insights into Myeloma and Other B Cell Malignancies. BioMed Research International, 2016, 2016, 1-3.	0.9	3
54	Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis. Mediators of Inflammation, 2016, 2016, 1-10.	1.4	17

#	Article	IF	Citations
55	Do Cancer Drugs Counteract Neurodegeneration? Repurposing forÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 1295-1306.	1.2	32
56	Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood, 2016, 127, 1138-1150.	0.6	89
57	APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood, 2016, 127, 3225-3236.	0.6	244
58	Exploiting tumor vulnerabilities: NAD⁺-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies. Expert Review of Anticancer Therapy, 2016, 16, 897-898.	1.1	0
59	Dual NAMPT and BTK Targeting Leads to Synergistic Killing of WaldenstrÃ¶m Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. Clinical Cancer Research, 2016, 22, 6099-6109.	3.2	19
60	The KDM3Aâ€“KLF2â€“IRF4 axis maintains myeloma cell survival. Nature Communications, 2016, 7, 10258.	5.8	87
61	Sirt6 regulates dendritic cell differentiation, maturation, and function. Aging, 2016, 8, 34-47.	1.4	28
62	Targeting Inflammation in Primary Cardiovascular Prevention. Current Pharmaceutical Design, 2016, 22, 5662-5675.	0.9	23
63	Abstract 3283: APRIL/BCMA activation promotes human multiple myeloma progression and further induces immunosuppressive bone marrow microenvironment. , 2016, , .		0
64	SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia. Blood, 2016, 128, 5222-5222.	0.6	0
65	CD38 Deregulation As Strategy to Make Multiple Myeloma Cells More Sensitive to NAD+ Depleting Agents. Blood, 2016, 128, 5671-5671.	0.6	0
66	EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition. BMC Cancer, 2015, 15, 855.	1.1	13
67	Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. BioMed Research International, 2015, 2015, 1-8.	0.9	13
68	APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells. Clinical Cancer Research, 2015, 21, 3934-3945.	3.2	31
69	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Reports, 2015, 12, 622-635.	2.9	123
70	Treatment with KLEPTOSEÂ® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response. Vascular Pharmacology, 2015, 72, 197-208.	1.0	14
71	A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia. Blood, 2015, 126, 1375-1375.	0.6	1
72	Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition. Oncotarget, 2015, 6, 11820-11832.	0.8	67

#	Article	IF	Citations
73	The KDM3A-KLF2-IRF4 Axis Maintains Myeloma Cell Survival. Blood, 2015, 126, 3633-3633.	0.6	0
74	Nicotinamide Phosphoribosyltransferase Promotes Epithelial-to-Mesenchymal Transition as a Soluble Factor Independent of Its Enzymatic Activity. Journal of Biological Chemistry, 2014, 289, 34189-34204.	1.6	64
75	CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia, 2014, 28, 155-165.	3.3	250
76	Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. Leukemia Research, 2014, 38, 649-659.	0.4	38
77	The SOCS3-Independent Expression of IDO2 Supports the Homeostatic Generation of T Regulatory Cells by Human Dendritic Cells. Journal of Immunology, 2014, 192, 1231-1240.	0.4	72
78	Novel antiâ€“B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood, 2014, 123, 3128-3138.	0.6	361
79	Potentiation of crizotinib activity by fasting cycles in an ALK+ lung cancer model.. Journal of Clinical Oncology, 2014, 32, e13511-e13511.	0.8	2
80	Synthesis of Pyrrolidine 3,4-Diol Derivatives with Anticancer Activity on Pancreatic Tumor Cells. Heterocycles, 2014, 88, 1445.	0.4	3
81	Synthesis and cancer growth inhibitory activities of 2-fatty-alkylated pyrrolidine-3,4-diol derivatives. Arkivoc, 2014, 2014, 197-214.	0.3	11
82	Abstract 972: B-cell maturation antigen (BCMA) activation in human multiple myeloma cells promotes myeloma cell growth and survival in the bone marrow microenvironment via upregulated MCL-1 and NFÎºB signaling. , 2014, , .		0
83	Abstract 644: Novel anti-B cell maturation antigen-monomethyl auristatin F antibody-drug conjugate (GSK2857916) induces potent and selective anti-multiple myeloma activity via enhanced effector function and direct tumor cell killing. , 2014, , .		0
84	A Novel Anti-a Proliferation-Inducing Ligand Hapril.01A Monoclonal Antibody Targets Multiple Myeloma Cells in the Bone Marrow Microenvironment. Blood, 2014, 124, 2098-2098.	0.6	0
85	Intracellular NAD⁺depletion induces autophagic death in multiple myeloma cells. Autophagy, 2013, 9, 410-412.	4.3	31
86	Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status. Leukemia and Lymphoma, 2013, 54, 342-352.	0.6	8
87	New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. Current Pharmaceutical Design, 2013, 19, 734-744.	0.9	38
88	Autophagy in blood cancers: biological role and therapeutic implications. Haematologica, 2013, 98, 1335-1343.	1.7	54
89	Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity. Blood, 2013, 122, 1243-1255.	0.6	74
90	Editorial (Thematic Issue: Chronic Myeloid Leukemia: Reaching For the Cure). Current Cancer Drug Targets, 2013, 13, 709-710.	0.8	0

#	Article	IF	Citations
91	New Insights Into Biology of Chronic Myeloid Leukemia: Implications in Therapy. Current Cancer Drug Targets, 2013, 13, 711-723.	0.8	10
92	Non Homologous End Joining, a Marker Of Genomic Instability Is Elevated In Multiple Myeloma: A New Prognostic Factor. Blood, 2013, 122, 124-124.	0.6	10
93	Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience. Current Drug Targets, 2013, 14, 637-643.	1.0	48
94	Evaluating Treatment Response of Chronic Myeloid Leukemia: Emerging Science and Technology. Current Cancer Drug Targets, 2013, 13, 779-790.	0.8	15
95	Nicotinamide Phosphoribosyltransferase as a Target in Inflammation- Related Disorders. Current Topics in Medicinal Chemistry, 2013, 13, 2930-2938.	1.0	27
96	Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience. Current Drug Targets, 2013, 999, 1-6.	1.0	0
97	Role Of Sirtuin-6 In Maintenance Of Genomic Instability In Multiple Myeloma Cells. Blood, 2013, 122, 276-276.	0.6	0
98	Constitutive B-Cell Maturation Antigen (BCMA) Activation In Human Multiple Myeloma Cells Promotes Myeloma Cell Growth and Survival In The Bone Marrow Microenvironment Via Upregulated MCL-1 and NFÎºB Signaling. Blood, 2013, 122, 681-681.	0.6	0
99	Identification Of Novel Alternative Splice Variants Of Sirtuins In Multiple Myeloma: Therapeutic Implications. Blood, 2013, 122, 3121-3121.	0.6	0
100	Novel Fc-Engineered Anti-B Cell Maturation Antigen-Monomethyl Auristatin F Antibody-Drug Conjugate (GSK2857916) Induces Potent and Selective Anti-Multiple Myeloma Activity Via Enhanced Effector Function and Direct Tumor Cell Killing. Blood, 2013, 122, 877-877.	0.6	1
101	New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Current Pharmaceutical Design, 2013, 19, 734-44.	0.9	23
102	Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood, 2012, 120, 1877-1887.	0.6	162
103	Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood, 2012, 120, 3519-3529.	0.6	133
104	The NAD+-dependent Histone Deacetylase SIRT6 Promotes Cytokine Production and Migration in Pancreatic Cancer Cells by Regulating Ca2+ Responses. Journal of Biological Chemistry, 2012, 287, 40924-40937.	1.6	151
105	Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker.. Blood, 2012, 120, 2932-2932.	0.6	3
106	New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. Current Pharmaceutical Design, 2012, 19, 734-744.	0.9	1
107	Abstract 2934: Targeting Bruton's tyrosine kinase with PCI-32765 blocks growth and survival of multiple myeloma and WaldenstrÃ¶m macroglobulinemia via potent inhibition of osteoclastogenesis, cytokines/chemokine secretion, and myeloma stem-like cells in the bone marrow microenvironment. , 2012. . .		0
108	CRM1 Blockade by Novel Inhibitors of Nuclear Export (SINEs) Inhibits Multiple Myeloma Cell Growth, Osteoclastogenesis, and Myeloma-Induced Osteolysis. Blood, 2012, 120, 326-326.	0.6	1

#	Article	IF	Citations
109	Compromised Nuclear Sirtuins Activity Sensitizes BRCA-Proficient multiple Myeloma Cells to DNA Damage Agents. Blood, 2012, 120, 723-723.	0.6	0
110	Intracellular NAD+ Depletion Enhances Bortezomib-Induced Myeloma Cytotoxicity. Blood, 2012, 120, 330-330.	0.6	0
111	Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells. PLoS ONE, 2011, 6, e22739.	1.1	68
112	Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. Bioorganic and Medicinal Chemistry, 2011, 19, 7720-7727.	1.4	13
113	Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma. Blood, 2011, 118, 2913-2913.	0.6	2
114	How Much Skin in the Game?. Journal of Structured Finance, 2011, 17, 54-58.	0.1	0
115	Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells. Blood, 2011, 118, 2920-2920.	0.6	0
116	Peripheral blood vs. bone marrow for molecular monitoring of BCRâ€ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. International Journal of Laboratory Hematology, 2010, 32, 387-391.	0.7	11
117	Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition. Current Cancer Drug Targets, 2010, 10, 168-175.	0.8	26
118	Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as Î±-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. Bioorganic and Medicinal Chemistry, 2010, 18, 3320-3334.	1.4	24
119	Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. Experimental Hematology, 2010, 38, 979-988.	0.2	48
120	A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib. Leukemia Research, 2010, 34, e240-e242.	0.4	15
121	Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5353-5356.	1.0	4
122	Grb7 Upregulation Is a Molecular Adaptation to HER2 Signaling Inhibition Due to Removal of Akt-Mediated Gene Repression. PLoS ONE, 2010, 5, e9024.	1.1	35
123	Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives. Clinical and Developmental Immunology, 2010, 2010, 1-14.	3.3	20
124	Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment.. Blood, 2010, 116, 1215-1215.	0.6	1
125	Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE. PLoS ONE, 2009, 4, e7897.	1.1	143
126	APO866 activity in hematologic malignancies: a preclinical in vitro study. Blood, 2009, 113, 6035-6037.	0.6	24

#	Article	IF	Citations
127	Potent Synergistic Activity of the NAD+ Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 2733-2733.	0.6	28
128	Deacetylase Inhibitor Cocktails Provide Striking Synergistic Interactions in Human Leukemia Cells.. Blood, 2009, 114, 4404-4404.	0.6	0
129	Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE.. Blood, 2009, 114, 4732-4732.	0.6	0